Agreed. Senior Leadership needs to go back to school, because they obviously have no idea what increasing shareholder value means.
I'm staying, but management does suck. Lots of institutions in this one, so maybe they have the inside scoop on something big.
These low volume sell off's for no reason really suck. I know its a long time until they get delisted, but from here it going to be tough to not have a reverse split.
Very few speculative bio's have revenue, and they have .71 a share in cash on hand. The market cap will be dictated by the future value of the company, and that is dictated by the size of the market they are trying to reach. Diabetes is a huge market.
$26 million market cap is complete #$%$. Maybe the presentation on October 22nd will help the pp.
I misspoke. They should have around .70 a share in cash, which is why its ridiculous its trading at these levels.